Encorafenib/binimetinib induced severe liver injury in a melanoma patient: Case report and review of literature
Encorafenib/binimetinib combination is approved for BRAF mutated melanoma and is being increasing used. The landmark COLUMBUS trial reports <10% incidence of any liver related injury markers and no cases of severe liver injury from the regimen was noted. We report a 48-year-old male with severe l...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-12-01
|
| Series: | Current Problems in Cancer: Case Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666621921000351 |